Nextgen Biomed Ltd (TASE: NXGN-M)
Health Care · Pharmaceuticals · IL
₪—
— today · — 1Y
Nextgen Biomed Ltd (TASE: NXGN-M) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.30M and employs 3 people.
trading between 0.11 and 0.76.
Tweenvest scores Nextgen Biomed Ltd across four factors: quality 13/100. Its strongest factor is quality.
NXGN-M price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.30M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.93
- Dividend yield
- —
- Beta (5Y)
- 0.50
- 52-week high
- ₪0.76
- 52-week low
- ₪0.11
- Avg volume (3M)
- —
- Shares outstanding
- 14.80M
- Employees
- 3
- Next earnings
- —
About Nextgen Biomed Ltd
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
- ISIN
- IL0010839301
- Founded
- 1990
- Listed since
- Aug 12, 2002
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,243.40 | -0.96% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.46 | +1.19% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.49 | -1.35% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.98 | -0.32% |
Figures last refreshed Aug 18, 2026.